Replies to post #58448 on $Stock*Shop*Charts*News*Option$

[Stock Lobster]

Re SRGLE:

http://www.surgilight.com/

On October 31, 2006 SurgiLight received conditional approval

from the FDA to expand its clinical trials to three (3) sites and on March 29, 2007 to expand to eight (8) sites.

On April 27, 2007 SurgiLight filed an 8-K with the SEC announcing a line of credit financing with Global Emerging Markets and related organizational restructuring.

Read the 8-K on the Investors page.


http://www.surgilight.com/Investors.htm

PATENTS

As part of the acquisition from Premier Laser Systems, the Company

acquired 14 patents and an additional 13 pending patents covering

the infrared technology, certain applications in cataracts, glaucoma and

other refractive surgeries. The Company also has 5 granted patents

and 15 patents pending in the U.S. for presbyopia reversal. The

Company has also received 2 international patents and submitted 9

international patents which are pending. The Company designates

most significant markets worldwide for patent coverage during its

international phase including, but not limited to, Japan, Canada, Israel,

Mexico, major countries in Europe, China, Taiwan and Australia.

[Stock Lobster]

SRGLE: in 2002, the SEC stated that Surglight's claims of being able to reverse presbyopia were 'baseless'. They also said being able to reverse presbyopia, which affects nearly every adult over the age of 40, would be the 'holy grail' for the laser surgery industry. (Does that mean it would generate $$$$$??? Hmmm.) see link: http://www.sec.gov/litigation/complaints/complr17469.htm

Yet, despite the SEC case against SRGLE's founder/director (the P&D accusations may be valid), two years later, articles like this were published about the technology (does someone owe someone else an apology? not sure. More importantly, what does this mean for the company today, and it's prospects for the future?)

12-month results positive for laser presbyopia reversal

Oct 22, 2004

Ophthalmology Times Meeting E-News

New Orleans—Laser presbyopia reversal (LAPR) is showing significant promise and patient satisfaction based on 12-month follow-up results from a U.S. clinical trial, said Sandra C. Belmont, MD, at the refractive surgery subspecialty day meeting.

Dr. Belmont is a principal investigator in the two-center study that is being conducted at Weill Cornell Medical College, New York, and with Jon Siems, MD, at his private clinic in Las Vegas.

The procedure involves use of an erbium:YAG laser (OptiVision, SurgiLight) to create eight radial incisions in the sclera. The study enrolled 60 eyes of 30 patients with a mean age of 53 years (range 50-58). The eligibility criteria required patients to have accommodation (2.5 D, stable manifest refraction between -4.5 and +7.5 D, normal IOP, (0.75 D astigmatism, and no prior ophthalmic surgery.

Patients were able to read immediately after surgery, and at 12 months, the group demonstrated a statistically significant increase in near UCVA, with 90% achieving J3 or better. In addition, 100% of eyes had >1 D increased amplitude of accommodation with a mean increase of 2.4 D. One patient with a poor 12-month near vision outcome had resumed spectacle wear. Safety was favorable with no changes in IOP or corneal topography.

Other measurements showed the surgery resulted in an approximate 10-mm increase in circumferential diameter of the globe along with a statistically significant decrease in axial length and a statistically significant decrease in anterior chamber depth, which might reflect forward movement of the crystalline lens.

From the perspective of the surgeon, this procedure is easy to learn, although it takes about 45 minutes per eye, and so far, the patients are very happy, although it is important to make sure they do not return to wearing their glasses or they will lose the effect, Dr. Belmont said.

The trial is now being expanded to eight sites in the United States. LAPR is being performed in the Pacific Rim and recently received an approvability letter for the CE mark.

[Stock Lobster]

Inspired by SRGLE, ABPH and TCLL I think I'm going to start a Lotto Board Home for Troubled Stocks...lol! Should HPNN be invited? I'm still deciding.

or, maybe an article for Parade Magazine:

'when good stocks go bad' how bickering, infighting and a pigheaded/and or jailed CEO can drive the most promising companies into walking the streets in penny hell.

Seriously, it's very sad to see real companies with verifiable first rate products, stocks which once sold for dollars, thrashing around in the penny muck with the rest of the trash. All because of a couple of bad decisions.

In the case of ABPH and SRGL, they both had advanced medical light & laser technology, were going great guns with pilot programs at prestigious medical centers, and then suddenly, a year or two ago, someone turned off the lights, but forgot to tell the investors. SRGL has real patents. I looked them up.

However, as far as cheapie dead-man-walking stocks go, I have to say ABPH has the better cob-web site. Surgilight's looks like a brain damaged monkey designed it. Chilling. Hope the monkey isn't doing eye surgery. See example "A": http://www.surgilight.com

And nobody is answering their phone. At least not today.

Time to hang up the "Gone Fishin'" sign on the door? Hope not.

[Stock Lobster]

SRGLE: the more I read the more interesting (and sad) the story is.

J.T. Lin, the PhD who created all these laser devices screwed up by getting involved with a pump and dump scheme on his own stock, and basically ended up having to sign over all of his patents to 'the company' in return for agreeing to quietly slithering away into the shadows. He hasn't been that good at it, though, and apparently has been contesting ownership of some of the patents, and spitefully allowing others to become abandoned, rather than see his former company take control of them.

At that point Collete Cozean became CEO. She was highly regarded in the industry, and was seen as a someone who could turn the company around. She came in with her team, but the problem, from what I can tell, is the company was already in the grips of GEM financing, a PIPE/so-called 'venture capital' company.

I think they'd been unhappy with the management for a year or two, as seen in the 2005 10K. Seems like they wanted the company to start diluting then to cover the convertibles, and when they didn't the GEM guys wanted to remove the directors:

http://209.85.165.104/search?q=cache:xj5QeE6EAlIJ:sec.edgar-online.com/2005/11/14/0001070289-05-0000....

Anyway, back to the most recent 8K which basically outlines three main points. 1) The resignation of the previous management team...the CEO and her hand picked team are out. Pressured out, I believe. 2) they've obtained new funding but at quite a cost: GEMs has all of their patents and copyrights as a lien and 3) the company has granted to GEM 55% of the company, plus the ability to appoint the board of directors, basically meaning that GEMS has taken over SRGLE.

So, given that there was mention in the 2005 10K of how certain parties felt that a 'potential acquisition' of surgilight was in the shareholders interest, and what was preventing it was the difficulty of removing the existing board of directors in Florida...you gotta wonder what they're going to do now that they own the company.

You see, the more I read up on the surgilight procedure, I realize it could be as big as lasik. It has huge potential around the world, plus in the united states.

At the heart of this .01 stock are these patents that slick players have been trying to get their hands on for a few years now. These GEM guys are slick, Wharton MBAs, senior Venture Capital people. Now, they basically own the company, and are one default away from owning the whole shebang.

I think they know what they've got their hands on....and I wouldn't be surprised if there is a acquisition partner already picked out.